Brief: Eiger Biopharmaceuticals Inc Received Notice Of Delisting From Nasdaq
28/07/2023 21:21
July 28 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* EIGER BIOPHARMACEUTICALS INC - ON JULY 26 RECEIVED NOTICE
OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview